protionamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2314 14222-60-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prothionamide
  • 2-Propylisonicotinylthioamide
  • 2-Propylthioisonicotinamide
  • protionamid
  • protionamide
Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents.
  • Molecular weight: 180.27
  • Formula: C9H12N2S
  • CLOGP: 2.26
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 38.91
  • ALOGS: -2.79
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.75 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 100 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.046 Moderate 0.77
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.505 Moderate 0.77
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 82.604 10^-6 cm/s Moderate 0.77
dh-clint Dog hepatocyte intrinsic clearance 17.219 uL/min/10^6 cells Moderate 0.77
dppb Dog plasma protein binding (% unbound) 44.840 % Moderate 0.77
fcs-ppb Fetal calf serum protein binding (% unbound) 54.310 % Moderate 0.77
herg hERG pIC50 4.112 pIC50 Moderate 0.77
hh-clint Human hepatocyte intrinsic clearance 4.634 uL/min/10^6 cells Moderate 0.77
hlm-clint Human liver microsomal intrinsic clearance 17.458 uL/min/mg protein Moderate 0.77
hppb Human plasma protein binding (% unbound) 40.670 % Moderate 0.77
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IRAK1,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 63
kinase-selectivity-class AXL,BRAF,EIF2AK3,GRK2 4
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.400 Moderate 0.77
mh-clint Mouse hepatocyte intrinsic clearance 90.365 Moderate 0.77
mppb Mouse plasma protein binding (% unbound) 41.950 Moderate 0.77
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.462 Moderate 0.77
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 52.010 % Moderate 0.77
rh-clint Rat hepatocyte intrinsic clearance 22.182 uL/min/10^6 cells Moderate 0.77
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.220 % Moderate 0.77
rppb Rat plasma protein binding (% unbound) 30.290 % Moderate 0.77
solubility-dd Solubility at pH 7.4 in DMSO 787.046 uM Moderate 0.77

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 84.07 48.65 25 391 72431 90555600
Hepatotoxicity 76.41 48.65 21 395 45821 90582210
Paradoxical drug reaction 74.06 48.65 14 402 5752 90622279
Drug resistance 60.29 48.65 16 400 30433 90597598

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatotoxicity 240.38 52.56 60 655 25107 42595513
Electrocardiogram QT prolonged 130.17 52.56 43 672 47902 42572718

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatotoxicity 309.17 44.70 81 1112 63319 110524787
Electrocardiogram QT prolonged 206.91 44.70 67 1126 108893 110479213
Neuropathy peripheral 68.75 44.70 35 1158 179242 110408864
Drug resistance 61.38 44.70 23 1170 56351 110531755

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AD01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Thiocarbamide derivatives
ATC J04AM10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM11 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000995 Antitubercular Agents
CHEBI has role CHEBI:33231 antitubercular agent

Related Drugs by ATC class:

J04AD Thiocarbamide derivatives 2 drugs
ethionamidetiocarlide
J04AM Combinations of drugs for treatment of tuberculosis 11 drugs
ethambutolisoniazidlevofloxacinlomefloxacinpyrazinamiderifabutinrifampicinstreptomycinsulfamethoxazolethioacetazonetrimethoprim

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.43 acidic
pKa2 5.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Polyphenol oxidase 2 Enzyme IC50 5.35 CHEMBL

External reference:

IDSource
N0000167317 NUI
D01195 KEGG_DRUG
C0033705 UMLSCUI
CHEBI:32066 CHEBI
CHEMBL1378024 ChEMBL_ID
DB12667 DRUGBANK_ID
14280 IUPHAR_LIGAND_ID
2031 INN_ID
76YOO33643 UNII
666418 PUBCHEM_CID
8871 RXNORM
006706 NDDF
703589003 SNOMEDCT_US
714517006 SNOMEDCT_US
D011515 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None